- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07941453
Pneumatic Displacement With Anti-VEGF and Concomitant rtPA for PCV-related Submacular Hemorrhage (PACT-PCV)
The Added Value of Recombinant Tissue Plasminogen Activator (rtPA) in Pneumatic Displacement of Submacular Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy (PCV) With Concomitant Anti-VEGF Therapy: A Prospective Randomized Controlled Trial
The goal of this randomized clinical trial is to determine whether adding recombinant tissue plasminogen activator (rtPA), a clot-dissolving medicine, to gas injection and anti-VEGF treatment improves outcomes in people with submacular hemorrhage (SMH) caused by polypoidal choroidal vasculopathy (PCV).
The main questions it aims to answer are:
- Does adding rtPA increase the proportion of participants with complete displacement of blood from beneath the fovea, the center of the macula, at 1 week after treatment?
- Does adding rtPA improve vision at 6 months and reduce complications, particularly vitreous hemorrhage (bleeding into the gel inside the eye) within 1 month after treatment?
Researchers will compare two pneumatic displacement (PD) strategies: anti-VEGF treatment plus C3F8 gas and rtPA (triple PD) and anti-VEGF treatment plus C3F8 gas without rtPA (dual PD). This comparison will assess the additional benefits and risks of rtPA. The study will enroll 80 participants at a single center. Participants will be randomly assigned to one of the two groups, with an equal chance of receiving either treatment.
The primary outcome is complete SMH displacement at 1 week, defined as no remaining blood beneath the fovea on optical coherence tomography (OCT), a scan that produces detailed images of the retina. Secondary outcomes include changes in best-corrected vision at 6 months, vitreous hemorrhage within 1 month, retinal detachment and other serious complications during follow-up, and the number of anti-VEGF injections over 6 months.
Participants will:
- Undergo baseline eye examinations, vision testing, and retinal imaging.
- Receive injections of anti-VEGF medicine and C3F8 gas into the affected eye, with or without rtPA, according to their assigned group.
- Follow the prescribed face-down positioning instructions for 3 days after treatment.
- Attend follow-up visits at 1 week and at 1, 3, and 6 months after treatment for vision testing, eye examinations, and retinal imaging, and receive further anti-VEGF treatment as needed.
Descripción general del estudio
Estado
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 4
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Fang Zheng
- Número de teléfono: +86 18258499106
- Correo electrónico: tjmuzxf@163.com
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Fovea-involving submacular hemorrhage (SMH) secondary to polypoidal choroidal vasculopathy (PCV), with a hemorrhage area of ≥2 optic disc areas and a subfoveal clot thickness of ≥300 μm.
- An interval of ≤14 days between symptom onset and planned treatment.
- Willingness to participate in the study and provision of written informed consent.
Exclusion Criteria:
- Unwillingness to undergo pneumatic displacement (PD).
- A history of previous SMH.
- Untreated retinal tears, retinal degenerative lesions, or other ocular conditions that make PD unsuitable.
- Concurrent significant vitreous hemorrhage that interferes with postoperative examination and treatment outcome assessment.
- Previous vitrectomy or other ocular surgery that may affect macular structure or the assessment of visual function.
- Coexisting ocular diseases, such as severe cataract, glaucoma, or uveitis, that may interfere with postoperative visual acuity assessment.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Triple PD (Anti-VEGF + Gas + rtPA)
Intravitreal injection of an anti-VEGF agent, intravitreal injection of rtPA (off-label), and intravitreal gas injection for pneumatic displacement. |
Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage. Intravitreal injection of rtPA as an off-label adjunct to pneumatic displacement, administered only in the triple PD arm at the dose specified in the study protocol, to promote clot liquefaction and facilitate submacular hemorrhage displacement. Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms. |
|
Comparador activo: Dual PD (Anti-VEGF + Gas)
Intravitreal injection of an anti-VEGF agent and intravitreal gas injection for pneumatic displacement. |
Intravitreal injection of an anti-VEGF agent (specific agent and dose per study protocol) as part of pneumatic displacement treatment for PCV-related submacular hemorrhage. Intravitreal gas injection (gas type and volume per study protocol) followed by post-injection positioning, performed to displace submacular hemorrhage away from the fovea. This procedure is used in both study arms. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rate of complete SMH displacement at 1 week after the procedure.
Periodo de tiempo: 1 week after procedure
|
No residual submacular hemorrhage in the foveal area on OCT. |
1 week after procedure
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of vitreous hemorrhage (VH) and proportion undergoing vitrectomy due to VH within 1 month after the procedure
Periodo de tiempo: Within 1 month after the procedure
|
Incidence of vitreous hemorrhage within 1 month after the procedure and the proportion of participants requiring pars plana vitrectomy (PPV) because of vitreous hemorrhage. |
Within 1 month after the procedure
|
|
Incidence of severe postoperative complications, including retinal detachment
Periodo de tiempo: Within 3 months after the procedure
|
Incidence of severe complications after the procedure, including retinal detachment. |
Within 3 months after the procedure
|
|
Change in best-corrected visual acuity (BCVA) at 6 months
Periodo de tiempo: At 6 months after the procedure
|
Change from baseline in best-corrected visual acuity (BCVA) at 6 months after the procedure, to assess visual prognosis. |
At 6 months after the procedure
|
|
Macular anatomical outcomes at 6 months
Periodo de tiempo: At 6 months after the procedure
|
Recovery of macular anatomy at 6 months after the procedure, including central macular thickness (CMT) , pigment epithelium detachment (PED) volume, and SMH absorption/resolution, to assess anatomical prognosis. |
At 6 months after the procedure
|
|
Number of anti-VEGF injections within 6 months after the procedure
Periodo de tiempo: Within 6 months after the procedure
|
Total number of anti-VEGF injections administered within 6 months after the procedure. |
Within 6 months after the procedure
|
Colaboradores e Investigadores
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades de los ojos
- Enfermedades uveales
- Enfermedades de la coroides
- Metaplasia
- Neovascularización coroidea
- Neovascularización Patológica
- Condiciones Patológicas, Signos y Síntomas
- Vasculopatía coroidea polipoidea
- Aminoácidos, péptidos y proteínas
- Proteínas
- Factores biológicos
- Hidrolasas
- Enzimas
- Enzimas y coenzimas
- Proteínas de la sangre
- Endopeptidasas
- Hidrolasas peptídicas
- Serina endopeptidasas
- Serina proteasas
- Activadores de plasminógeno
- Factores de coagulación de sangre
- Activador del plasminógeno tisular
Otros números de identificación del estudio
- 2 0 2 6 - 0 6 5 2
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .